Squamous cell carcinoma of the skin is treated primarily through surgery, with the specific approach depending on the tumor’s size, location, and whether it has spread. When caught early, the five-year survival rate is 99 percent. Most people will have their cancer removed in an outpatient procedure and recover within a few weeks, though advanced cases may require immunotherapy, radiation, or a combination of treatments.
Surgery: The First-Line Treatment
Surgery is the most common and most effective treatment for squamous cell carcinoma. The two main surgical options are standard excision and Mohs micrographic surgery, and which one you get depends largely on how aggressive the cancer looks under a microscope and where it sits on your body.
In a standard excision, a surgeon cuts out the tumor along with a margin of healthy-looking skin around it. The removed tissue is sent to a lab to confirm the edges are cancer-free. This works well for lower-risk tumors on areas like the trunk or limbs.
Mohs surgery is a more precise technique where the surgeon removes thin layers of tissue one at a time, examining each layer under a microscope during the procedure itself. This continues until no cancer cells remain. It’s particularly valuable for tumors on the face, ears, or hands, where preserving as much healthy tissue as possible matters for function and appearance. A 2025 study from the American College of Surgeons compared the two approaches in 216 patients with high-grade squamous cell carcinomas. Over a median follow-up of about 33 months, local recurrence was roughly twice as common with standard excision (19.8 percent) compared to Mohs surgery (9.6 percent). Metastasis rates were also higher in the excision group (17.9 percent versus 11 percent). Based on these findings, the study authors recommended Mohs or similar margin-checking techniques as the primary treatment for high-grade tumors.
Curettage and Electrodesiccation
For small, superficial squamous cell carcinomas, a simpler in-office procedure called curettage and electrodesiccation (ED&C) is sometimes used. The doctor scrapes away the cancerous tissue with a specialized instrument, then applies an electric current to destroy remaining cancer cells and stop bleeding. This cycle is typically repeated two or three times in the same session.
This approach is generally reserved for low-risk tumors in certain locations. Dermatologists tend to avoid it on the central face (the area around the eyes, nose, and lips) because recurrence risk is higher there and scarring can be more noticeable. It’s more commonly offered to patients who may not tolerate a full surgical procedure well, such as those on blood thinners, those with multiple medical conditions, or those with cognitive impairments that make lengthy procedures difficult. Tumor location and patient health are the two biggest factors in deciding whether ED&C is appropriate.
Topical Treatments for Early-Stage Disease
When squamous cell carcinoma is confined entirely to the outermost layer of skin (called “in situ,” meaning it hasn’t invaded deeper tissue), topical creams can sometimes replace surgery. The most studied option is a chemotherapy cream containing 5-fluorouracil, applied directly to the affected area over several weeks.
Treatment duration makes a significant difference in how well this works. In a study published in the Journal of the American Academy of Dermatology, tumors treated for four weeks or longer had a 93.2 percent complete clearance rate, compared to 86.7 percent for two to four weeks of treatment and just 57.1 percent for less than two weeks. Shorter treatment was strongly linked to treatment failure. Patients using this cream typically experience redness, crusting, and discomfort at the application site, which is expected and actually signals the medication is working.
Photodynamic Therapy
Photodynamic therapy (PDT) is another option for very superficial squamous cell carcinomas in situ. A light-sensitizing chemical is applied to the skin, allowed to absorb into the cancerous cells, and then activated by a specific wavelength of light. The activated chemical generates a reaction that destroys the abnormal cells.
The initial complete response rate in one retrospective review of 68 lesions was about 78 percent. However, the technique is sensitive to how long the chemical sits on the skin before light exposure. When incubation time was under three hours, only 53.3 percent of lesions cleared, compared to 84.9 percent with longer incubation. Among those that initially cleared, about 13 percent recurred within a year. PDT is best suited for patients who want to avoid surgery on cosmetically sensitive areas, but it requires careful technique and close follow-up because of these recurrence rates.
Radiation Therapy
Radiation is used in two main scenarios: as a primary treatment when surgery isn’t feasible, or as a follow-up after surgery when the cancer had concerning features like close margins or spread to nearby nerves.
The American Society for Radiation Oncology recommends definitive radiation as primary treatment for patients who are not good surgical candidates, whether because of medical conditions, age, or the tumor’s location. It’s also an option when surgery would cause significant cosmetic or functional problems, such as removing a large tumor near the eye or on the ear. In those situations, the decision is typically made collaboratively between the patient and their care team. Radiation is delivered over multiple sessions, with the exact number varying based on tumor size and location. Each session is painless and takes only a few minutes, though the full course may span several weeks.
Immunotherapy for Advanced Cases
When squamous cell carcinoma grows too large for surgery or spreads to lymph nodes or distant organs, immunotherapy becomes the primary treatment. These drugs work by blocking a protein called PD-1 that cancer cells use to hide from the immune system. Once that shield is removed, the body’s own immune cells can recognize and attack the tumor.
The most established immunotherapy for advanced squamous cell carcinoma is cemiplimab, which has been extensively studied in both locally advanced and metastatic disease. Pooled data from phase 1 and phase 2 clinical trials showed an objective response rate of about 46 percent, meaning nearly half of patients saw their tumors shrink significantly. Response rates were similar whether the cancer was locally advanced (44 percent) or had spread to distant sites (45.2 percent). These are meaningful numbers for cancers that were previously very difficult to treat.
Pembrolizumab, another PD-1 blocker originally approved for other cancers, is also used in this setting. For patients whose cancer doesn’t respond to immunotherapy alone, or who stop responding over time, combining immunotherapy with a targeted therapy that blocks a growth signal called EGFR is showing promise. In one trial, adding cetuximab (an EGFR blocker) to pembrolizumab at the time of disease progression restored tumor response in 44 percent of patients. A separate randomized trial found this combination significantly improved the time before cancer worsened compared to immunotherapy alone, though it also came with more side effects.
When Cancer Has Spread: What the Numbers Look Like
The vast majority of squamous cell carcinomas are caught before they spread, and the prognosis at that stage is excellent. The five-year survival rate for localized disease is 99 percent. Once the cancer has spread beyond the skin, that number drops below 50 percent. This stark difference is the reason dermatologists emphasize regular skin checks and prompt treatment of suspicious lesions. Catching squamous cell carcinoma while it’s still confined to the skin is overwhelmingly the most important factor in outcomes.
Recovery and Follow-Up After Treatment
Recovery from surgical removal is straightforward for most people. After excision or Mohs surgery, a scab forms over the wound and typically peels away on its own within one to three weeks, depending on the body area treated. Your doctor will give you specific wound care instructions, which usually involve keeping the site clean, applying petroleum jelly, and protecting it from sun exposure while it heals. Larger excisions or those requiring skin flaps or grafts take longer and may involve activity restrictions for a few weeks.
Having one squamous cell carcinoma significantly increases your risk of developing another. Follow-up visits are scheduled at regular intervals, typically every few months for the first couple of years and then less frequently. During these visits, a dermatologist examines the treated site for recurrence and checks the rest of your skin for new cancers. Most recurrences happen within the first two years, making this window the most critical period for monitoring.